ArticleMolecular cancer therapeutics2018

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.

Elaine T Lam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.